ResearcherSemmelweis UniversityNo recent work listed
Attila Oláh
Matched on ORCID iD 0000-0001-7609-5366; OpenAlex author ID A5038766805. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 37
2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper
Papers 6
- [Surgery of the pancreatic cancer - Expected standards]. Co-author DOI 10.1556/1046.2023.10003↗
- The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
- Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
- Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
- [Pancreatic cancer. Evidence based management guidelines of the Hungarian Pancreatic Study Group]. Co-author DOI 10.1556/oh.2015.30063↗
- Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗
Closest collaborators
The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christos Dervenis · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Alan Anthoney · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Paula Ghaneh · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Bengt L. G. Glimelius · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Daniel H. Palmer · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Niall Christopher Tebbutt · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- John P. Neoptolemos · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Julia V. Mayerle · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Juan W. Valle · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Christopher Michael Halloran · 4 shared papers, 2014–2019 · strength 0.20
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- David Goldstein · 3 shared papers, 2018–2019 · strength 0.18
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Markus M. Lerch · 3 shared papers, 2018–2019 · strength 0.18
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Markus Wolfgang Büchler · 3 shared papers, 2014–2019 · strength 0.15
- Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. DOI 10.1093/jnci/djt347↗
- William Greenhalf · 3 shared papers, 2014–2018 · strength 0.14
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Paper Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. DOI 10.1093/jnci/djt347↗
- Eithne Costello · 3 shared papers, 2014–2018 · strength 0.14
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Paper Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. DOI 10.1093/jnci/djt347↗
- Richard Charnley · 3 shared papers, 2014–2018 · strength 0.14
- Paper Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. DOI 10.1038/s41416-018-0004-2↗
- Paper Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related … DOI 10.1038/s41416-018-0005-1↗
- Paper Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. DOI 10.1093/jnci/djt347↗
- Nils O. Elander · 2 shared papers, 2018 · strength 0.11
- Karen Aughton · 2 shared papers, 2018 · strength 0.11
- Alexander C. McDonald · 2 shared papers, 2014–2019 · strength 0.09
- James Melling · 1 shared paper, 2019 · strength 0.06
- Owain Jones · 1 shared paper, 2019 · strength 0.06
- Derek A O'Reilly · 1 shared paper, 2019 · strength 0.06
- Robert Padbury · 1 shared paper, 2019 · strength 0.06
- Oliver Strobel · 1 shared paper, 2019 · strength 0.06
- Jakob Robert Izbicki · 1 shared paper, 2019 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.